Roche Reports Mixed Data for Drug Trying to Jump on the Biologic Bandwagon in COPD

Roche Reports Mixed Data for Drug Trying to Jump on the Biologic Bandwagon in COPD

Roche’s astegolimab met the main goal of one pivotal COPD study but failed another, mirroring the mixed results recently posted by a Regeneron Pharmaceuticals COPD drug candidate that goes after the same target. Biologics are a new treatment option for COPD following approvals of antibodies from Sanofi and GSK. The post Roche Reports Mixed Data for Drug Trying to Jump on the Biologic Bandwagon in COPD appeared first on MedCity News.

Roche Suffers Setback as Lung Drug Gets Mixed Result in Trial

Roche Holding AG’s experimental drug for a deadly lung condition got mixed results in trials, a setback as the company seeks to accelerate the development of new treatments.

Mixed results from Roche’s mAb in COPD

Roche's mAb for COPD met its primary endpoint in the Phase IIb study, but not in the Phase III trial.The post Mixed results from Roche’s mAb in COPD appeared first on Clinical Trials Arena.

Inhaled Pharmacotherapy for Stable COPD

This JAMA Clinical Guidelines Synopsis summarizes the 2025 Global Strategy for the Diagnosis, Management, and Prevention of COPD.